SCHEMBL16712923

SCHEMBL16712923

COc1ccc(C(=O)Cl)cc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ CTSA P10619 1/20 0.50
▸ SYK P43405 2/20 0.48
▸ AURKB Q96GD4 2/20 0.48
▸ INCENP Q9NQS7 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ TPMT P51580 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ HSP90AB1 P08238 1/20 0.46
▸ CYP1A2 P05177 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20350806 0.87 MKNK1 (0.52) LMNAALDH1A1KMT2ACA12CA1
SCHEMBL402416 0.87 CA12 (0.62) LMNAALDH1A1KMT2ACTSASYK
SCHEMBL8891409 0.86 BACE1 (0.54) LMNAALDH1A1KMT2ASYKAURKB
SCHEMBL16712926 0.86 POLB (0.49) LMNAALDH1A1KMT2AHPGDTTR
SCHEMBL9524595 0.85 SYK (0.63) LMNAALDH1A1KMT2ACTSASYK
SCHEMBL6934114 0.85 HSP90AA1 (0.58) LMNAALDH1A1SYKHSP90AA1HSP90AB1
SCHEMBL16712924 0.85 PDE4D (0.54) LMNAALDH1A1KMT2ACTSAHSP90AA1
SCHEMBL5991136 0.84 MKNK1 (0.56) LMNAALDH1A1KMT2ACTSASYK
SCHEMBL35823 0.84 PTGS2 (0.58) LMNAALDH1A1KMT2ACTSASYK
SCHEMBL3205541 0.84 LMNA (0.59) LMNATDP1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis THE UNIVERSITY OF CHICAGO (US) 2025-04-22 — — US disclosed
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2024-12-19 — — US disclosed
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2022-06-09 — — US disclosed
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2022-02-10 — — US disclosed
EP-3946301-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS The University of Chicago (US) 2022-02-09 — — EP disclosed
WO-2020206118-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2020-10-08 — — WO disclosed
WO-2020206109-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2020-10-08 — — WO disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A LMNA 4244/4885ALDH1A1 2857/4885KMT2A 4122/4885
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS MYLK, MFAP1, FIBP LMNA 2969/4885ALDH1A1 3220/4885KMT2A 3269/4885
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis MYLK, MFAP1, FIBP LMNA 2969/4885ALDH1A1 3220/4885KMT2A 3269/4885
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A LMNA 4244/4885ALDH1A1 2857/4885KMT2A 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback